A pedestrian passes in entrance of 200 West Street, which homes the headquarters of Goldman Sachs Group Inc., in New York.
Scott Eells | Bloomberg | Getty Images
Goldman Sachs is making its U.S. employees report whether or not they’ve taken one of the Covid-19 vaccines, in accordance to an inside memo despatched this week.
Employees should inform the New York-based financial institution by midday Thursday on their status, in accordance to the memo. Last month, Goldman instructed its workforce that they need to be ready to return to offices within the U.S. and United Kingdom by June 14.
“Registering your vaccination status allows us to plan for a safer return to the office for all of our people as we continue to abide by local public health measures,” the memo stated. “As a result, it is mandatory that you submit your vaccination status on the Canopy app, whether or not you are vaccinated.” Canopy is the financial institution’s in-house portal for worker updates.
While it is legal for firms to ask employees about their vaccination status, they have to maintain that info confidential. Many employers have been loath to power workers to take the vaccine or present proof of photographs, as a substitute counting on an honor system.
Until now, disclosing vaccination status had been voluntary on the funding financial institution, which has about 40,000 employees globally, in accordance to The New York Times’ DealBook, which first reported on the memo. Only these employees who hadn’t already instructed the financial institution about their status obtained the message, a financial institution spokesperson instructed CNBC.
Goldman employees are being requested to publish the date and model of their vaccination however do not have to present proof of the inoculation, in accordance to the Times.
“While we strongly encourage you to receive a COVID-19 vaccine, we understand that the choice to get vaccinated is a personal one,” the financial institution stated within the memo.
Become a wiser investor with CNBC Pro.
Get inventory picks, analyst calls, unique interviews and entry to CNBC TV.
Sign up to begin a free trial today.